Association of PD-L1 expression and clinical outcomes in ROS1-rearranged advanced non-small cell lung cancer treated with entrectinib.

Transl Lung Cancer Res · 2026 · PMC13186671 · PMID 42170258

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceP=0.39not close (p > 0.1)

showed a trendno p-value reported

However, PD-L1 high expression group (TPS ≥50%) showed a trend toward longer survival (n=4; mPFS =15.93 months, 95% CI: 3.13–NE) compared to PD-L1-negative patients (n=11; mPFS =5.33 months, 95% CI: 4.37–NE), though this difference did not reach statistical significance (P=0.39, Figure 3D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.